CS1 CAR-T treatment for myeloma after prior BCMA CAR-T
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies CAR-T cells (a type of immune therapy) that target CS1 in people with multiple myeloma that has come back after earlier BCMA CAR-T. It may help control the cancer when previous CAR-T therapy or other treatments were not enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed multiple myeloma that is CS1-positive (and/or BCMA-negative)
- You previously had BCMA CAR-T therapy and your myeloma is back, or you meet specific relapse patterns like after transplant, repeat low-level disease, or hard-to-treat outside-the-bone areas
- You are expected to live more than 12 weeks
- You are 30 to 75 years old and can give informed consent
- You have not had any CAR-T or other genetically modified immune cell therapies before
- You do not have major brain/heart problems, pregnancy or breastfeeding, serious infections, or major liver/kidney test abnormalities
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a lab-made immune treatment (BCMA-targeted CAR-T cells) for people with relapsed or refractory multiple myeloma who have limited options. It may help your body recognize and attack myeloma cells.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
This early-phase study tests a CAR-T cell treatment made to target BCMA and TACI proteins in multiple myeloma. It may help people whose myeloma has come back or did not respond to prior treatments, especially after certain prior therapies.
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
This study tests a new cell therapy called CS1 CAR-T, which helps your immune system attack myeloma cells that still grow after several other treatments. It's for people who have already tried at least three different types of therapy.
Hear when a new Relapse Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.